Dendritic cells and cancer immunotherapy

Highlights • DC vaccines can induce anti-tumour responses and show clinical benefit. • DC subsets specialised in Ag cross-presentation are key for anti-tumour responses. • Targeting tumour Ag and adjuvants to CD141+ DC in vivo offers promise for DC therapy. • DC therapies can be improved by overcomi...

Full description

Saved in:
Bibliographic Details
Published in:Current opinion in immunology 2014-04, Vol.27, p.26-32
Main Authors: Radford, Kristen J, Tullett, Kirsteen M, Lahoud, Mireille H
Format: Article
Language:English
Subjects:
Allergy and Immunology
Animals
Antigens, Neoplasm - immunology
Cancer Vaccines - immunology
Dendritic Cells - immunology
Humans
Immunotherapy
Neoplasms - immunology
Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • DC vaccines can induce anti-tumour responses and show clinical benefit. • DC subsets specialised in Ag cross-presentation are key for anti-tumour responses. • Targeting tumour Ag and adjuvants to CD141+ DC in vivo offers promise for DC therapy. • DC therapies can be improved by overcoming immune suppression and immune regulation.
ISSN:0952-7915
1879-0372
DOI:10.1016/j.coi.2014.01.005